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o r i g i n a l a r t i c l e
Daily Bathing with Chlorhexidine-Based Soap and the Prevention of
Staphylococcus aureus Transmission and Infection
Melissa A. Viray, MD;1 James C. Morley, PhD;2 Craig M. Coopersmith, MD;3 Marin H. Kollef, MD;1
Victoria J. Fraser, MD;1 David K. Warren, MD, MPH1
objective. Determine whether daily bathing with chlorhexidine-based soap decreased methicillin-resistant Staphylococcus aureus (MRSA)
transmission and intensive care unit (ICU)–acquired S. aureus infection among ICU patients.
design. Prospective pre-post-intervention study with control unit.
setting. A 1,250-bed tertiary care teaching hospital.
patients. Medical and surgical ICU patients.
methods. Active surveillance for MRSA colonization was performed in both ICUs. In June 2005, a chlorhexidine bathing protocol was
implemented in the surgical ICU. Changes in S. aureus transmission and infection rate before and after implementation were analyzed
using time-series methodology.
results. The intervention unit had a 20.68% decrease in MRSA acquisition after institution of the bathing protocol (12.64 cases per
1,000 patient-days at risk before the intervention vs 10.03 cases per 1,000 patient-days at risk after the intervention; b, 2.62 [95%
confidence interval (CI), 5.19 to 0.04]; P p .046). There was no significant change in MRSA acquisition in the control ICU during
the study period (10.97 cases per 1,000 patient-days at risk before June 2005 vs 11.33 cases per 1,000 patient-days at risk after June 2005;
b, 11.10 [95% CI, 37.40 to 15.19]; P p .40). There was a 20.77% decrease in all S. aureus (including MRSA) acquisition in the
intervention ICU from 2002 through 2007 (19.73 cases per 1,000 patient-days at risk before the intervention to 15.63 cases per 1,000
patient-days at risk after the intervention [95% CI, 7.25 to 0.95]; P p .012)]. The incidence of ICU-acquired MRSA infections decreased
by 41.37% in the intervention ICU (1.96 infections per 1,000 patient-days at risk before the intervention vs 1.15 infections per 1,000
patient-days at risk after the intervention; P p .001).
conclusions. Institution of daily chlorhexidine bathing in an ICU resulted in a decrease in the transmission of S. aureus, including
MRSA. These data support the use of routine daily chlorhexidine baths to decrease rates of S. aureus transmission and infection.
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Staphylococcus aureus is a major cause of healthcare-associated
infections, particularly among critically ill patients. Methi-
cillin-resistant S. aureus (MRSA) has caused an increasing
proportion of intensive care unit (ICU)–acquired S. aureus
infections in the United States over the past 20 years. Com-
pared with methicillin-susceptible S. aureus (MSSA), MRSA
infections are associated with increased costs1-3 and mortal-
ity.4,5
Transmission of S. aureus between hospitalized patients has
long been felt to primarily occur via the hands of healthcare
workers.6 Multiple interventions have been undertaken to
interrupt MRSA transmission in healthcare settings, including
improving healthcare worker hand hygiene compliance, in-
stituting contact precautions for patients colonized or in-
fected with MRSA, performing active surveillance to identify
asymptomatic colonization and prompt earlier contact pre-
cautions, and decolonizing MRSA-colonized patients.7 Chlor-
hexidine gluconate, a topical antiseptic, has been used in
preprocedural skin antisepsis and to eliminate MRSA car-
riage. Recent data have emerged to support the use of chlor-
hexidine skin antisepsis to prevent the transmission of drug-
resistant organisms, such as vancomycin-resistant enterococci
(VRE) and MRSA, in ICUs.8-10 Several studies have evaluated
the use of chlorhexidine-based skin antisepsis, with or with-
out intranasal therapy to decolonize MRSA-colonized ICU
patients,11-14 and reported decreases in MRSA acquisition,11
colonization,12,13 and infection.13,14 Additionally, bathing all
ICU patients daily with a chlorhexidine-based soap has been
shown to decrease acquisition of MRSA,8,15 colonization with
MRSA16 and MRSA infection.17 However, few studies8,17 ex-
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table 1. Characteristics of the Intervention and Control Intensive Care Units
Variable
Intervention (surgical) ICU
(Dec 2002–Dec 2007)
Control (medical) ICU
(Jan 2005–Dec 2007) P a
No. of beds 24 19 NA
Patient days, totalb 35,124 18,402 NA
Ventilator utilization ratio, monthly, median (range)b 0.69 (0.45–0.80) 0.59 (0.43–0.68) !.001
Central venous catheter utilization ratio, monthly, median
(range)b 0.66 (0.44–0.81) 0.59 (0.46–0.76) .008
Patient characteristics, monthly proportion, median (range)c
Decubitus ulcer (stage II or greater) 0.23 (0.14–0.38) 0.22 (0.16–0.34) .08
Tracheostomy 0.20 (0.11–0.54) 0.18 (0.11–0.25) .003
Enteral tube feeding 0.28 (0.17–0.69) 0.22 (0.17–0.40) .004
MRSA colonization at admission 0.17 (0.06–0.38) 0.24 (0.13–0.38) !.001
note. ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; NA, not applicable.
a Determined by Mann-Whitney U test.
b Patients with more than a 2-day stay in the ICU only.
c Proportion of all ICU admissions with variable of interest during ICU stay, per month.
amining the effect of routine daily chlorhexidine bathing on
S. aureus transmission and infection have accounted for sec-
ular trends in colonization pressure because of changes in
MRSA prevalence or changes in patient mix among patients
admitted to the ICU. Additionally, few studies have concom-
itantly compared the use of chlorhexidine in intervention
units with its use in nonintervention units.10,18
The objective of this study was to determine whether a
daily bathing protocol with a chlorhexidine-based soap de-
creased intra-unit MRSA transmission among ICU patients.
A secondary goal was to determine whether chlorhexidine-
bathing reduced intra-unit overall S. aureus (ie, regardless of
susceptibility to methicillin) transmission and ICU-acquired
S. aureus infection. These outcomes were compared with out-
comes in an ICU in which bathing with nonmedicated soap
was performed. The use of time series methodology allowed
us to address potential confounders, such as temporal trends
in patient mix and the prevalence of S. aureus colonization
at ICU admission over time.
methods
This study was performed at Barnes-Jewish Hospital (BJH),
a 1,250-bed, urban, tertiary-care teaching hospital in St.
Louis, Missouri. During the period of study, the trauma and
surgical ICU (SICU) had 24 beds and approximately 1,400
admissions per year. The 19-bed medical ICU (MICU) had
approximately 1,500 annual admissions. Patients with a pre-
vious or current history of MRSA, VRE, Clostridium difficile–
associated diarrhea, and certain multidrug-resistant gram-
negative bacilli were routinely placed under contact
precautions, in accordance with hospital policy.
S. aureus (both methicillin-susceptible S aureus and MRSA)
active surveillance data were available for the intervention
unit (SICU) from January 2002 and for the control unit
(MICU) from January 2005. The study intervention was per-
formed in June 2005, and study activities continued through
December 2007. For the purposes of our analyses, all available
data from each ICU were included for primary and secondary
outcomes.
Nasal cultures for S. aureus were performed for all patients
admitted to these ICUs for more than 12 hours. Nasal cultures
were also performed weekly and at ICU discharge for all
patients staying in the ICU more than 48 hours. Decoloni-
zation therapy for MRSA with topical mupirocin was not
routinely performed at BJH during the study period. Micro-
biological analysis of nasal specimens has been previously
described.19 Methicillin resistance among S. aureus clinical
isolates was determined using standard microbiological meth-
ods. All positive routine clinical cultures for S. aureus (ie,
MRSA and MSSA) were recorded.
Bathing Protocol
Patient bathing in both units before June 2005 consisted of
basin baths with nonmedicated soap (Aloe Vesta 2-n-1 Body
Wash & Shampoo; ConvaTec) at least daily and additionally
throughout the day if needed after bowel movements or other
episodes of blood or body fluid soiling. In June 2005, the
surgical ICU switched to using 4% chlorhexidine–based soap
(Exidine 4%; Cardinal Health) for daily patient bathing. One
4-ounce bottle of chlorhexidine-based soap was added to 4
quarts of water, to give an approximate final concentration
of 0.125% chlorhexidine gluconate in the bath water. Bathing
was done with wash cloths using a standard method.20 Chlor-
hexidine bathing was not performed above the neck, on the
perineum, or on open wounds. Bathing compliance in the
surgical ICU during the postintervention period was assessed
weekly by determining the total number of chlorhexidine
bottles used versus the total number of patient-days.
Data Collection and Definitions
Prospective collection of patient-level data occurred in the
surgical ICU from January 2002 through December 2007 and
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table 2. Comparison of Methicillin-Resistant Staphylococcus aureus (MRSA) Acquisition Rates in the Intervention
Intensive Care Unit (ICU), 2002–2007, and Control ICU, 2005–2007
Variable Intervention (surgical) ICUa P Control (medical) ICU P
Crude rate per 1,000 patient-days at riskb
Before intervention 12.64 10.97
After intervention 10.03 11.33
Change, % 20.68 3.28
Time series model, b (95% CI)c
Intervention 2.62 (5.19 to 0.04) .046 11.10 (37.40 to 15.19) .395
Adjusted MRSA colonization pressured 30.79 (8.74–52.85) .007 22.90 (13.36 to 59.16) .207
AR(1) ... ... 0.33 (0.02 to 0.67) .061
MA(4) ... ... 0.89 (1.00 to 0.79) !.001
Constant 6.75 (2.14–11.35) .005 17.72 (11.61 to 47.04) .227
Model parameters
Adjusted R2 0.14 0.32
Durbin-Watson statistic 2.08 1.84
Q(4) P ... .71 ... .65
Q(8) P ... .55 ... .55
Q(12) P ... .62 ... .73
note. The inclusion of autoregressive (AR) and moving average (MA) terms in the model addressed serial correlation
seen, as evidenced by the Durbin-Watson statistic and the Box-Ljung Q(k) tests of the unadjusted model. AR(1), AR
variable 1; CI, confidence interval; MA(4), MA variable 4.
a Models are based on all available data for the surgical ICU (61 months, 2002–2007) and medical ICU (24 months,
2005–2007).
b See “Methods” for definition of patient-days at risk.
c In the multivariate time series model, b indicates the magnitude and the direction of the variable in the model, whereas
the P value and 95% CI indicate the precision and significance of the variable within the model.
d Other factors considered for inclusion in the final model included decubitus ulcers, tracheostomy, enteral feedings,
central venous catheter utilization ratio, and mechanical ventilator utilization ratio.
in the medical ICU from January 2005 through December
2007 as part of an ongoing study of S. aureus transmission
that has been previously described.21 Data collected for all
surgical and medical ICU patients included demographic
characteristics, hospital and ICU admission and discharge
dates, previous admission to BJH in the past 12 months, the
patient’s location before hospital admission, and use of con-
tact precautions. Additional data were collected for patients
who remained in the ICU for more than 48 hours, including
their past medical history, ICU processes of care, and use of
mechanical ventilation and/or central venous catheters. En-
teral tube feeding was defined as feeding via a nasogastric,
Dobhoff, gastrostomy, jejunostomy, or gastrojejunostomy
tube.
S. aureus colonization at ICU admission was defined as a
patient having an admission nasal surveillance culture pos-
itive for S. aureus or any clinical culture positive for S. aureus
within 48 hours after ICU admission. To determine the num-
ber of patients coming into the unit already carrying S. aureus,
incoming colonization pressure was defined as the number
of patients colonized or infected with S. aureus at admission
per total number of admissions per month. S. aureus acqui-
sition was defined as an admission nasal surveillance culture
negative for S. aureus and subsequent isolation of S. aureus
from a surveillance or clinical culture performed more than
48 hours after admission. The S. aureus acquisition rate was
defined as the number of acquired S. aureus cases per 1,000
patient-days at risk, where a day at-risk was defined as a day
in the ICU (not within the first 48 hours after admission)
without evidence of any S. aureus colonization or infection.18
ICU-related S. aureus infections and device utilization ratio
were defined using the Centers for Disease Control and Pre-
vention criteria.19
Analysis
The primary outcome of the analysis was the effect of the
bathing intervention on MRSA acquisition in the intervention
ICU (SICU) versus the control ICU (MICU). Times series
analysis of the primary outcome was performed using data
from the intervention ICU (SICU) from January 2002
through December 2007 and from the control ICU (MICU)
from January 2005 through December 2007. The secondary
outcomes were S. aureus acquisition (ie, both methicillin-
susceptible and methicillin-resistant bacteria) as well as ICU-
acquired infection due to MRSA and all S. aureus within the
intervention ICU. The unit of analysis for each ICU was 1
month. The monthly proportion of patients admitted to each
unit with that characteristic, or who developed it during their
ICU hospitalization, was calculated. A time series model was
developed for each ICU with use of ordinary least squares
regression. First-order serial autocorrelation and higher-order
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figure 1. Unadjusted rates of methicillin-resistant Staphylococcus aureus (MRSA) acquisition per 1,000 patient-days at risk for the inter-
vention intensive care unit.
autocorrelation were assessed for each model using Durbin-
Watson statistic and Box-Ljung Q(k) test, respectively. Be-
cause autocorrelation was present in the control ICU, an
autoregressive moving average model was created for the pri-
mary outcome; an autoregressive part and a moving average
part were included in this model. Because the hypothesis of
the study is that overall colonization pressure should decrease
as a result of the intervention, an instrumental variable “ad-
justed colonization pressure” was created to account for var-
iation in colonization pressure attributable to changes over
time in the proportion of patients already colonized at the
time of ICU admission. This is expressed as
ˆX { X  p 7 D ,adj. pressure, t pressure, t t
where Dt is the binary variable for the intervention. The
Andrews-Ploberger test for a break in mean at an unknown
date22 was performed to determine the month with the max-
imal change in mean MRSA transmission rate in both units.
All analysis was conducted in EViews 6 (IHS Global). The
Wilcoxon rank-sum test was used to examine differences be-
tween medians. This study was approved by the Washington
University Human Research Protection Office.
results
During the study periods mentioned above, data were col-
lected for a total of 53,526 patient-days, 35,124 from the
intervention ICU and 18,402 from the control ICU (Table
1). There was higher use of central lines and ventilators in
the intervention ICU than in the control ICU as well as a
higher monthly proportion of patients receiving enteral feeds
and having tracheostomies. MRSA colonization at admission
to the ICU was higher in the control ICU (median proportion
of patients with MRSA colonization at admission, 0.24 vs
0.17 per month; P ! .001). No other interventions were im-
plemented during the periods of study that substantively af-
fected S. aureus acquisition and/or infection rates.
The intervention unit had a 20.68% decrease in MRSA
acquisition after institution of the chlorhexidine bathing pro-
tocol in June 2005 (12.64 cases per 1,000 patient-days at risk
before intervention vs 10.03 cases per 1,000 patient-days at
risk after intervention; b, 2.62 [95% confidence interval
(CI), 5.19 to 0.04]; P p .046; Table 2; Figure 1). The
reduction in MRSA acquisition was similar when intervention
compliance (measured by antiseptic soap bottles used per
patient-day) was used in the model (data not shown). There
was no significant change in MRSA acquisition in the control
ICU after June 2005 (10.97 cases per 1,000 patient-days at
risk before June 2005 vs 11.33 cases per 1,000 patient-days
at risk after June 2005; b, 11.10 [95% CI, 37.40 to 15.19];
P p .40). To account for changes in MRSA prevalence at the
time of ICU admission, adjusted MRSA colonization pressure
was included in the final model (Table 2). Other factors, such
as the proportion of ICU patients with decubitus ulcers or
the monthly central venous catheter device utilization ratio,
were not significant in the multivariable model. By the
Andrews-Ploberger test, July 2005 was the month in the in-
tervention unit with the maximal change in MRSA acquisition
(1 month after the intervention started).
Using June 2005 as the breakpoint for analysis in both
units, there was a 41.37% decrease in MRSA infection in the
intervention ICU (1.96 infections per 1,000 ICU-days before
the intervention vs 1.15 infections per 1,000 ICU-days after
the intervention). There was no significant change in the
prevalence of MRSA infection in the control ICU (2.19 in-
fections per 1,000 ICU-days before June 2005 vs 1.05 infec-
tions per 1,000 ICU-days after June 2005; b, 1.51 [95% CI,
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table 3. Comparison of Methicillin-Resistant Staphylococcus aureus (MRSA) Infection Rates in the Intervention
Intensive Care Unit (ICU), 2002–2007, and Control ICU, 2005–2007
Variable Intervention (surgical) ICUa P Control (medical) ICU P
Crude rate per 1,000 ICU-days
Before intervention 1.96 2.19
After intervention 1.15 1.05
Change, % 41.37 51.95
Time series model, b (95% CI)b
Intervention 0.90 (1.40 to 0.40) .001 1.51 (4.01 to 1.00) .228
Adjusted MRSA colonization pressure 10.78 (5.41–16.15) !.001 1.37 (1.76 to 4.51) .377
AR(1) ... 0.57 (0.91 to 0.24) .002
AR(2) ... 0.38 (0.69 to 0.07) .018
MA(5) 0.36 (0.62 to 0.11) .005 ...
MA(9) 0.30 (0.53 to 0.08) .009 ...
MA(10) 0.31 (0.57 to 0.06) .017 ...
MA(12) ... 0.93 (1.00 to 0.86) !.001
Constant 0.13 (1.33 to 1.06) .822 2.32 (0.18 to 4.82) .068
Model parameters
Adjusted R2 0.42 0.70
Durbin-Watson statistic 2.12 2.37
Q(4) ... .24 ... .28
Q(8) ... .66 ... .54
Q(12) ... .90 ... .40
note. The inclusion of autoregressive (AR) and moving average (MA) terms in the model addressed serial correlation
seen, as evidenced by the Durbin-Watson statistic and the Box-Ljung Q(k) tests of the unadjusted model. AR(1), AR
variable 1; AR(2), AR variable 2; CI, confidence interval; MA(5), MA variable 5; MA(9), MA variable 9; MA(10), MA
variable 10; MA(12), MA variable 12.
a Models are based on all available data for the surgical ICU (61 months, 2002–2007) and medical ICU (24 months,
2005–2007).
b In the multivariate time series model, b indicates the magnitude and the direction of the variable in the model,
whereas the P value and 95% CI indicate the precision and significance of the variable within the model.
4.01 to 1.00]; P p .228; Table 3). There was a 20.78%
decrease in all S. aureus acquisition in the intervention ICU
from 2002 to 2007 (19.73 cases per 1,000 patient-days at risk
before the intervention vs 15.63 cases per 1,000 patient-days
at risk after the intervention; b, 4.1 [95% CI, 7.25 to
0.95; P p .012; Table 4). There was no change in S. aureus
acquisition from 2005 to 2007 in the control ICU (19.21 cases
per 1,000 patient-days at risk before June 2005 vs 15.33 cases
per 1,000 patient-days at risk after June 2005; b, 6.75 [95%
CI, 20.75 to 7.26]; P p .334). ICU-acquired S. aureus in-
fection rates also decreased by 34.31% in the intervention
ICU (2.71 S. aureus infections per 1,000 ICU-days before the
intervention vs 1.78 S. aureus infections per 1,000 ICU-days
after the intervention; Table 5), but not in the control ICU
(2.19 S. aureus infections per 1,000 ICU-days before June
2005 vs 1.98 S. aureus infections per 1,000 ICU-days after
June 2005; b, 1.58 [95% CI, 1.31 to 4.47]; P p .273).
discussion
Institution of daily chlorhexidine bathing in a surgical ICU
resulted in a decrease in the acquisition of and infections with
S. aureus, including MRSA. This effect persisted even when
accounting for temporal changes in S. aureus and MRSA
colonization pressure at admission to the ICU and other pa-
tient risk factors. There was no significant decrease in S. au-
reus and MRSA acquisition or infections during an overlap-
ping time frame in the control ICU, which did not implement
chlorhexidine bathing.
The use of time-series analysis allows for evaluation of the
impact of an intervention while controlling for issues related
to changes in S. aureus and MRSA colonization pressure
among newly admitted patients, differences in patient co-
morbidities and severity of illness, and seasonality. This is
important because external trends in MRSA prevalence at
admission to the ICU can affect subsequent changes in ob-
served rates of S. aureus transmission and infection, inde-
pendent of a particular intervention. The use of an instru-
mental variable, adjusted colonization pressure, to account
for the changes in the S. aureus and MRSA colonization pres-
sure present at ICU admission is novel.
Additional evidence supporting causality includes our find-
ing that the maximal change in the MRSA monthly acqui-
sition rate (as measured by the Andrews-Ploberger test) co-
incided with the implementation of chlorhexidine bathing in
the intervention unit, whereas no change was seen during the
same time frame in a control unit that was within the same
hospital but did not use chlorhexidine bathing. This supports
our findings and reduces the risk that observed decreases in
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table 4. Time Series Models for Staphylococcus aureus Acquisition Rates in the Intervention Intensive Care Unit (ICU),
2002–2007, and Control ICU, 2005–2007
Variable Intervention (surgical) ICUa P Control (medical) ICU P
Crude rate per 1000 patient-days at riskb
Before intervention 19.73 19.21
After intervention 15.63 15.33
Change, % 20.78 20.18
Time series model, b (95% CI)c
Intervention 4.10 (7.25 to 0.95) .012 6.75 (20.75 to 7.26) .334
Adjusted S. aureus colonization pressure 49.13 (26.21–72.04) .000 25.96 (15.38 to 67.31) .210
AR(1) ... 0.24 (0.13 to 0.61) .191
MA(4) ... 0.38 (0.74 to 0.02) .039
Constant 2.40 (5.99 to 10.79) .569 12.50 (9.77 to 34.76) .261
Model parameters
Adjusted R2 0.28 0.10
Durbin-Watson statistic 1.90 1.99
Q(4) ... .83 ... .81
Q(8) ... .87 ... .87
Q(12) ... .87 ... .88
note. The inclusion of autoregressive (AR) and moving average (MA) terms in the model addressed serial correlation
seen, as evidenced by the Durbin-Watson statistic and the Box-Ljung Q(k) tests of the unadjusted model. AR(1), AR
variable 1; CI, confidence interval; MA(4), MA variable 4.
a Models are based on all available data for the surgical ICU (61 months, 2002–2007) and medical ICU (24 months, 2005–
2007).
b See “Methods” for definition of patient-days at risk.
c In the multivariate time series model, b indicates the magnitude and the direction of the variable in the model, whereas
the P value and 95% CI indicate the precision and significance of the variable within the model.
S. aureus and MRSA acquisition and infection rates in the
ICU using chlorhexidine were attributable to seasonal vari-
ation or other unmeasured confounders. Even when exam-
ined in the time period from 2005 to 2007 for both units,
the reduction in MRSA acquisition was still significant in the
intervention unit (data not shown).
These results expand on previous studies12,13 that demon-
strated that decolonization of S. aureus carriers identified by
active microbiologic surveillance using brief (7-day) periods
of daily chlorhexidine baths significantly decreased rates of
MRSA in an ICU. Ridenour et al13 reported a 52% decreased
rate of MRSA acquisition in the ICU, and Fraser et al12 dem-
onstrated a 47% decrease in S. aureus colonization incidence
and 63% decreased incidence in total S. aureus–related hos-
pital-acquired infections. However, these studies did not take
into account the impact of routine chlorhexidine bathing for
all patients over a longer period of time, which could have
an independent and potentially additive effect on S. aureus
carriage and acquisition. Several studies have examined the
effect of daily chlorhexidine bathing on ICU patients and
have reported decreases in the rates of healthcare-associated
infection10,16,18,23 and the transmission of VRE.9,10 Milstone et
al24 found decreased incidence in bacteremia in pediatric ICUs
in per-protocol analysis, but similar rates of S. aureus bac-
teremia, very possibly attributable to very small numbers of
positive cultures. Huang et al15 found comparable significant
decreases in MRSA-positive clinical cultures (37%, compared
with 41% seen in our study) after the institution of universal
decolonization with daily chlorhexidine baths and nasal mu-
pirocin. None of the studies were able to demonstrate de-
creased MRSA transmission.
Few studies8,11,17 have used time-series methodology to eval-
uate the impact of daily chlorhexidine bathing on MRSA in
ICUs. The use of time-series methodology allowed us to ad-
dress secular trends in colonization pressure, which might
otherwise bias our findings. Climo et al8 reported a multi-
center study using time-series analysis to evaluate daily bath-
ing with chlorhexidine and reported a 32% decrease in MRSA
acquisition but no difference in MRSA bacteremia. The de-
crease in reported MRSA acquisition was comparable to that
seen in our study. However, we also noted a 41.4% decrease
in all MRSA infections in the ICU using chlorhexidine bath-
ing. The difference might be explained by accounting for
incoming colonization pressure in our model. In a smaller
study, Gould et al17 evaluated daily chlorhexidine bathing as
one of multiple simultaneous interventions and found an
11.4% decrease in MRSA in their ICU and nonsignificant
decreases in MRSA bacteremia. However, because chlorhex-
idine bathing was only one of multiple interventions adopted
(which included active surveillance culturing and contact iso-
lation of colonized and infected patients), the effect of chlor-
hexidine bathing alone could not be determined.
Our study had some limitations. Although the use of time-
series methodologies and a concurrent control ICU addresses
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table 5. Time Series Models for Staphylococcus aureus Infection Rates in the Intervention Intensive Care Unit (ICU)
(2002–2007) and Control ICU (2005–2007)
Variable Intervention (surgical) ICUa P Control (medical) ICU P
Crude rate per 1,000 ICU-days
Before intervention 2.71 2.19
After intervention 1.78 1.98
Change, % 34.31 9.37
Time series model, b (95% CI)b
Intervention 0.87 (1.25 to 0.49) !.001 1.58 (1.31 to 4.47) .273
Adjusted S. aureus colonization pressure 11.35 (6.86–15.84) !.001 11.17 (6.39–15.95) !.001
AR(1) ... 0.40 (0.77 to 0.04) .032
AR(2) ... 0.36 (0.73 to 0.01) .059
MA(1) 0.21 (0.46 to 0.03) .083 ...
MA(5) 0.33 (0.57 to 0.09) .008 ...
MA(6) 0.44 (0.70 to 0.18) .001 ...
MA(7) ... 0.91 (0.99 to 0.83) !.001
Constant 1.37 (3.04 to 0.31) .107 3.63 (7.40 to 0.14) .059
Model parameters
Adjusted R2 0.35 0.46
Durbin-Watson statistic 2.09 1.87
Q(4) ... .14 ... .22
Q(8) ... .66 ... .18
Q(12) ... .71 ... .28
note. The inclusion of autoregressive (AR) and moving average (MA) terms in the model addressed serial correlation
seen, as evidenced by the Durbin-Watson statistic and the Box-Ljung Q(k) tests of the unadjusted model. AR(1), AR
variable 1; AR(2), AR variable 2; CI, confidence interval; MA(1), MA variable 1; MA(5), MA variable 5; MA(6), MA
variable 6; MA(7), MA variable 7.
a Models are based on all available data for the surgical ICU (61 months, 2002–2007) and medical ICU (24 months,
2005–2007).
b In the multivariate time series model, b indicates the magnitude and the direction of the variable in the model, whereas
the P value and 95% CI indicate the precision and significance of the variable within the model.
many potential confounders, this was not a randomized con-
trolled trial, and we cannot completely exclude the impact of
other unmeasured confounders or temporal trends on the
outcome. We did not evaluate length of stay (LOS) or mor-
tality using these data; there would be additional confounding
factors and/or interventions impacting LOS and mortality
that would need to be included in the model. A future ded-
icated study could be performed to look at the impact of
chlorhexidine bathing on those outcomes. We did not eval-
uate the MRSA strains in this study for the chlorhexidine
resistance loci (ie, qacA/B). Future studies will be needed to
determine whether widespread use of chlorhexidine for pa-
tient bathing will select for chlorhexidine tolerance in S. au-
reus and MRSA within healthcare settings and the community.
Our findings support the routine use of daily chlorhexidine
baths to decrease rates of S. aureus transmission and infection
in ICU settings. Chlorhexidine bathing is an inexpensive and
relatively simple measure to adopt. Additional studies are
needed to evaluate the effect of chlorhexidine bathing in non–
tertiary care centers as well as in noncritical care settings to
define the role of routine chlorhexidine bathing in healthcare
and to evaluate for the development of resistance to chlor-
hexidine and/or potential adverse events that might occur
with more widespread use of this topical antiseptic.
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